2025
Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial
Whalen M, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Hoffmann T, Aweeka F, Parikh S, Mwebaza N. Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. The Journal Of Clinical Pharmacology 2025 PMID: 39853752, DOI: 10.1002/jcph.6193.Peer-Reviewed Original ResearchDesbutyl-lumefantrineAntiretroviral therapyEfavirenz-based antiretroviral therapyEfavirenz-based HIV therapyEFV-based antiretroviral therapyEpisodes of malariaHIV co-infectionSignificant reductionExtended treatment durationStatistically significant reductionClinically significant reductionArtemether-lumefantrinePharmacodynamic trialsMalaria episodesPharmacokinetic samplingHIV therapyRandomized studyRecurrence riskDrug interactionsPrimary outcomeRegimensMalariaReinfection riskHIVCo-infection
2022
The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply